These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 19323898)

  • 1. Antithrombotic and antiplatelet therapies in relation to risk stratification in patients with non-ST elevation acute coronary syndrome: insights from the Sino-Global Registry of Acute Coronary Events.
    Zhang LJ; Chen YD; Song XT; Zhao FH; Lü SZ
    Chin Med J (Engl); 2009 Mar; 122(5):502-8. PubMed ID: 19323898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
    Budaj A; Brieger D; Steg PG; Goodman SG; Dabbous OH; Fox KA; Avezum A; Cannon CP; Mazurek T; Flather MD; Van De Werf F;
    Am Heart J; 2003 Dec; 146(6):999-1006. PubMed ID: 14660991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
    Banihashemi B; Goodman SG; Yan RT; Welsh RC; Mehta SR; Montalescot G; Kornder JM; Wong GC; Gyenes G; Steg PG; Yan AT;
    Am Heart J; 2009 Dec; 158(6):917-24. PubMed ID: 19958857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification.
    Oliveira GB; Avezum A; Anderson FA; Budaj A; Dabbous OH; Goodman SG; Steg PG; Goldberg RJ; Brieger D; Fox KA; Gore JM; Granger CB;
    Am Heart J; 2007 Apr; 153(4):493-9. PubMed ID: 17383284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE).
    Stiles MK; Dabbous OH; Fox KA;
    Heart Lung Circ; 2008 Feb; 17(1):5-8. PubMed ID: 17419100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of heparins in Non-ST-elevation acute coronary syndromes.
    Gore JM; Spencer FA; Goldberg RJ; Kennelly BM; Fox KA; Allegrone J; Eagle KA; Anderson FA; Steg PG;
    Am J Med; 2007 Jan; 120(1):63-71. PubMed ID: 17208081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events).
    Lim MJ; Eagle KA; Gore JM; Anderson FA; Dabbous OH; Mehta RH; Granger CB; Fox KA; Spencer FA; Goldberg RJ;
    Am J Cardiol; 2005 Oct; 96(7):917-21. PubMed ID: 16188516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
    Fitchett D; Goodman SG; Gupta M; Langer A
    Can J Cardiol; 2002 Nov; 18(11):1179-90. PubMed ID: 12464982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.
    Wang TY; Chen AY; Peterson ED; Becker RC; Gibler WB; Ohman EM; Roe MT
    Eur Heart J; 2008 May; 29(9):1103-9. PubMed ID: 18353757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for the early management of acute coronary syndromes: focus on antithrombotic and antiplatelet therapy.
    Fitchett D;
    Can J Cardiol; 2000 Nov; 16(11):1423-32. PubMed ID: 11109039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.
    Wang TY; Robinson LA; Ou FS; Roe MT; Ohman EM; Gibler WB; Smith SC; Peterson ED; Becker RC
    Am Heart J; 2008 Feb; 155(2):361-8. PubMed ID: 18215609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]).
    Gore JM; Spencer FA; Gurfinkel EP; López-Sendón J; Steg PG; Granger CB; FitzGerald G; Agnelli G;
    Am J Cardiol; 2009 Jan; 103(2):175-80. PubMed ID: 19121432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry.
    Yan AT; Yan RT; Huynh T; Casanova A; Raimondo FE; Fitchett DH; Langer A; Goodman SG;
    Arch Intern Med; 2009 Feb; 169(4):372-8. PubMed ID: 19237721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
    Mehta RH; Greenbaum AB; Lokhnygina Y; Newby LK; Van De Werf F; Armstrong PW; Pieper KS; Califf RM; Granger CB; Harrington RA
    J Interv Cardiol; 2007 Oct; 20(5):299-306. PubMed ID: 17880325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.